Cullinan Oncology reels in $98 million to advance cancer drug pipeline
Cullinan Oncology emerged nearly three years ago with an approach to cancer drugs its founders said would improve the odds of success. Now it has a pipeline of seven compounds and a fresh $98.5 million to advance all of them. The new cash announced recently is a Series B round of funding that added the financial backing of unnamed institutional investors and family offices.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063